Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lisata Therapeutics (LSTA) Accumulated Expenses (2016 - 2025)

Lisata Therapeutics filings provide 13 years of Accumulated Expenses readings, the most recent being $2.1 million for Q4 2025.

  • For the quarter ending Q4 2025, Accumulated Expenses fell 52.6% year-over-year to $2.1 million, compared with a TTM value of $2.1 million through Dec 2025, down 52.6%, and an annual FY2025 reading of $2.1 million, down 52.6% over the prior year.
  • Accumulated Expenses hit $2.1 million in Q4 2025 for Lisata Therapeutics, down from $3.9 million in the prior quarter.
  • The five-year high for Accumulated Expenses was $4.3 million in Q4 2024, with the low at $2.1 million in Q4 2025.
  • Median Accumulated Expenses over the past 3 years was $3.9 million (2023), compared with a mean of $3.7 million.
  • The sharpest move saw Accumulated Expenses rose 8.25% in 2024, then plummeted 52.6% in 2025.
  • Year by year, Accumulated Expenses stood at $4.2 million in 2023, then increased by 3.84% to $4.3 million in 2024, then crashed by 52.6% to $2.1 million in 2025.
  • According to Business Quant data, Accumulated Expenses over the past three periods came in at $2.1 million, $3.9 million, and $3.5 million for Q4 2025, Q3 2025, and Q2 2025 respectively.